The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

Simplify Health Care ETF (PINK) has delivered superior 1-year returns of 42% versus iShares U.S. Healthcare ETF's (IYH) 31.4%, driven by active management focused on healthcare innovation and a charitable mission donating profits to cancer research. However, IYH offers lower costs (0.38% vs 0.51% expense ratio), higher dividend yield (1.1% vs 0.6%), and a proven 25+ year track record, making it the more suitable choice for most long-term conservative investors despite PINK's recent outperformance.

The global gRNA (guide RNA) market is projected to grow from USD 518 million in 2024 to USD 2,950 million by 2034, representing a 19% CAGR. Growth is driven by increasing cancer research, infectious disease prevalence, technological innovation, and expanding applications in genome editing, functional genomics, diagnostics, cell & gene therapy, and agricultural biotechnology. Key market players include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, and others. Strategic partnerships and rising adoption of CRISPR technology in agriculture are major growth catalysts.

Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.

The global Deep Eutectic Solvents (DES) market is projected to grow from USD 177.64 million in 2024 to USD 735.89 million by 2034, at a CAGR of 15.27%. Growth is driven by increasing demand for sustainable, eco-friendly alternatives to conventional solvents across pharmaceuticals, food processing, and chemical industries. Key players include Proionic GmbH, Merck KGaA, BASF SE, Thermo Fisher Scientific, and Solvay S.A.

AGC Biologics has secured a multi-year commercial manufacturing contract worth hundreds of millions of dollars with an undisclosed international biopharmaceutical company for its new Yokohama facility in Japan. The agreement covers production of five biopharmaceutical products with at least 35 batches annually, reflecting growing industry demand for geopolitically stable and resilient supply chains. The Yokohama site is expected to begin operations in 2027 with 18,000 liters of single-use bioreactor capacity.

AGC Biologics has secured a multi-year commercial manufacturing contract worth hundreds of millions of dollars with a major global biopharmaceutical company for its new Yokohama facility. The customer will utilize half of the facility's mammalian cell-based production capacity to manufacture five biopharmaceutical products with minimum 35 batches annually. The facility, set to begin operations in 2027, reflects growing demand for geopolitically stable and reliable biopharmaceutical supply chains.

The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.

The global Pyridine & Pyridine Derivatives Market is projected to grow from USD 812.04 million in 2025 to USD 1,255.74 million by 2035, at a CAGR of 4.97%. Growth is driven by increasing demand from agrochemical and pharmaceutical industries, with pyridine leading product segments and herbicides dominating applications. Asia Pacific holds the largest market share at 48%, while the U.S. market is expected to reach USD 228.10 million by 2035.

The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.

The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth at 9.12% CAGR.